ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
By F. Cardoso, A. Costa, Larry Norton, E. Senkus, M. Aapro, F. André, C. Barrios, J. Bergh, L. Biganzoli, K. Blackwell and 33 more. Breast, 2014
634 citations recorded by the source corpus.
Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality of life. Due to continuous research, several advances have been made, particularly for the HER-2-positive and for Luminal-like subtypes. Notwithstanding these advances, median overall survival of patients with ABC is still only 2–3 years, although the range is wide [1–5], and survival may be longer for patients treated in specialized institutions [6]. Implementation of current knowledge is highly variable among countries and within each country.
Subfields: Cancer Research, Oncology
View Paper: https://www.semanticscholar.org/paper/28b5df1a55116972a1457f2f5628b23dce7995de
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
Citations in the corpus
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† (2018, background): “As already extensively discussed in previous editions, the main recommendation for these patients is the induction of OFS/OFA, to which an additional endocrine agent should be added [1, 11].”
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. (2021, background): “MBC after therapy for EBC tends to have a more aggressive tumour biology and a worse outcome compared with de novo MBC. 14,15 In a retrospective cohort study covering the period 1990-2010, 14 de novo MBC incidence rates remained constant whereas subsequent MBC decreased.”
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020, neutral): “For the purpose of advanced breast cancer (ABC) guidelines, ABC comprises both inoperable locally advanced breast cancer (LABC) and metastatic breast cancer (MBC).(1,2) Advanced/metastatic breast cancer remains a virtually”
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. (2017, background): “MONARCH 2 evaluated patients whose disease progressed while they were receiving neoadjuvant or adjuvant ET, # 12 months after adjuvant ET, or while receiving ET for ABC.”